REG - Angle PLC - Exclusive agreement for DNA NGS panel

AngleAnnouncement

23/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240923:nRSW1404Fa&default-theme=true

RNS Number : 1404F  Angle PLC  23 September 2024

 For immediate release  23 September 2024

 

 

ANGLE plc ("the Company")

 

ANGLE ANNOUNCES NEXT GENERATION SEQUENCING ASSAY AGREEMENT WITH NUPROBE

 

Option for exclusive licence to highly sensitive NGS assay for use with CTCs
and dual analysis of CTCs with ctDNA

 

Combining the Parsortix system with comprehensive DNA molecular analysis opens
up a broad range of pharma services opportunities

 

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with
innovative circulating tumour cell (CTC) solutions for use in research, drug
development and clinical oncology, is delighted to announce that it has signed
an agreement with the cutting-edge genomics and molecular diagnostics company,
NuProbe USA, Inc. ("NuProbe"), to use its proprietary pan-cancer next
generation sequencing (NGS) panel ("the NGS panel").

 

Under the terms of the agreement, NuProbe has granted the Company an option
for an exclusive global license to the NGS panel outside of China for the
analysis of CTCs and the dual analysis of CTCs and ctDNA. In this first stage
of the collaboration, NuProbe will transfer manufacture of the NGS panel to a
larger-scale manufacturing site and ANGLE will undertake internal validation
of the initial batches.

 

The NGS panel, which has been validated on the Illumina sequencer, enables
highly sensitive and specific detection of over 6,500 DNA mutations in 61
clinically relevant genes and been found to be the highest performing
multi-gene assay of those evaluated by ANGLE. These genes include those with
matched targeted therapies currently selected using assays which use tumour
tissue or circulating tumour DNA (ctDNA) and aligns with many key drug targets
under development by large pharma.

 

This agreement will help accelerate the Company's ability to commercialise its
first pan-cancer molecular sequencing assay either for CTC-DNA analysis alone
or dual analysis of CTCs and ctDNA from a single blood sample. The NGS panel
enables highly sensitive and specific high throughput gene analysis and has
immediate applicability to ANGLE's pharma services customers and translational
researchers using the Parsortix(®) system. In the longer-term, repeatable,
minimally invasive, molecular profiling using liquid biopsy analytes has the
potential to be a key step for clinicians tracking tumour evolution, treatment
response, early identification of drug resistance and disease progression.

 

The Company has already successfully completed a pilot study with the NGS
panel, with results published at the EACR Annual Meeting in June 2024 (see:
https://angleplc.com/resources/posters/
(https://angleplc.com/resources/posters/) ). In this study CTC-DNA (from CTCs
harvested using the Parsortix system) and ctDNA were evaluated in blood
samples from breast, lung and ovarian cancer patients. In all three cancer
types, more mutations were identified exclusively in CTCs, as compared to
ctDNA alone, highlighting the potential value of profiling CTCs in addition to
ctDNA.

 

NuProbe Chief Executive Officer, Yingshuang Chai, commented:

"We are excited to enter into an agreement with ANGLE plc, a world leader in
the harvest of CTCs from blood for analysis. NuProbe's NGS panel is a
low-cost, ultra-sensitive pan-cancer NGS panel that can accurately detect
mutations and has demonstrated robust performance in both CTC and ctDNA sample
types. By combining CTC and ctDNA detection, this collaboration will help
drive the development of personalised treatment options for cancer patients.
We look forward to the development of a strong partnership with ANGLE in the
future."

 

ANGLE Chief Executive Officer, Andrew Newland, commented:

"We are delighted to have signed an agreement with NuProbe which grants the
Company an exclusive worldwide licence option (outside of China) to the NGS
panel for the analysis of CTCs and dual analysis of CTCs and ctDNA. The
Company's marker-independent Parsortix system has been exemplified in 24
cancer types representing 90% of all solid tumour cases. As such we are
strongly positioned to leverage a pan-cancer gene panel across 61 oncogenes
and thousands of mutations.  The Company believes that this agreement will
enable us to combine the leading CTC harvesting solution with an optimised DNA
sequencing panel for analysis of CTCs and dual analysis of CTCs and ctDNA."

 

ANGLE Chief Scientific Officer, Karen Miller commented:

"We are pleased to sign an agreement with NuProbe which will support our
ongoing development of highly sensitive and specific molecular assays using
CTCs harvested using the Parsortix system together with ctDNA from a single
blood sample. Dual analysis of CTCs and ctDNA can provide additional and
complementary information which will provide pharma services customers with
unparalleled and repeatable insights into a range of cancers, and in the
longer-term provide clinicians with the potential for continual optimisation
of personalised cancer treatment plans."

 

 

For further information:

 

 ANGLE plc                               +44 (0) 1483 343434
 Andrew Newland, Chief Executive

 Ian Griffiths, Finance Director

 Berenberg (NOMAD and Broker)            +44 (0) 20 3207 7800

 Toby Flaux, Ciaran Walsh, Milo Bonser

 FTI Consulting

 Simon Conway, Ciara Martin              +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                +1 (212) 850 5624

 

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the EU Market Abuse
Regulation (596/2014). Upon the publication of this announcement via a
regulatory information service, this information is considered to be in the
public domain.

 

For Research Use Only. Not for use in diagnostic procedures.

 

For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
(https://angleplc.com/investor-relations/glossary/)

 

 

Notes for editors

 

About ANGLE plc

 

ANGLE is a world-leading liquid biopsy company with innovative circulating
tumour cell (CTC) solutions for use in research, drug development and clinical
oncology using a simple blood sample. ANGLE's FDA cleared and patent protected
circulating tumour cell (CTC) harvesting technology known as the Parsortix(®)
PC1 System enables complete downstream analysis of the sample including whole
cell imaging and proteomic analysis and full genomic and transcriptomic
molecular analysis.

 

ANGLE's commercial businesses are focusing on diagnostic products and clinical
services. Diagnostic products include the Parsortix(®) system and associated
consumables. The clinical services business is offered through ANGLE's
GCP-compliant laboratories in the UK. Services include custom made assay
development and clinical trial testing for pharma.

 

Over 90 peer-reviewed publications have demonstrated the performance of the
Parsortix system. For more information, visit www.angleplc.com
(http://www.angleplc.com)

 

About
NuProbe

 

NuProbe is a cutting-edge genomics and molecular diagnostics company with
revolutionary molecular diagnostic technologies to improve the sensitivity of
sequencing mutations and copy number variations by over 10-fold. NuProbe has
sites in Houston, USA, Shanghai, China and Suzhou, China. NuProbe's
vision is to offer affordable, timely, and accurate disease state information
to enable precision medicine and improve patient outcomes.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRDGGDCDSDDGSD